pharmaphorum
AUGUST 7, 2020
Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Under the terms of the agreement Pfizer will become one of several external partners who manufacture the investigational treatment for the disease.
Outsourcing Pharma
AUGUST 5, 2020
The firms are working to create a platform that gives the ability to monitor temperature-sensitive treatments, vaccines and other products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Druggist
AUGUST 3, 2020
Otrivine Extra Dual Relief is a pharmacy only medication and the only over the counter product containing ipratropium bromide for the management of congestion and runny nose caused by colds. This post summarises the essential information about Otrivine Extra Dual Relief nasal spray. 1. Otrivine Extra Dual Relief indicated use Otrivine Extra spray is used for the management of congestion and rhinorrhoea caused by colds. 2.
Pharma Marketing Network
AUGUST 3, 2020
Recently, the Healthcare Businesswomen’s Association (HBA) held a webinar entitled, Virtual Best Practices: Clarity, Collaboration and Connecting , which dove into the topic of “Zoom fatigue,” a new, commonly used term defined by the draining feeling you experience after a day of long, unnecessary meetings. We are all facing new challenges in the rapidly changing work environment.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
AUGUST 4, 2020
New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always faced challenges when it comes to HTA approvals, even as governments bring in more regulatory policies that make their path through assessment easier. Several factors make it difficult for HTA bodies often to assess orphan drugs, including a lack of robust trial data due to difficulties in finding patients, the absence of randomised controlled tri
Outsourcing Pharma
AUGUST 5, 2020
The bipartisan bill calls for an assessment of the countryâs pharma supply chain, including potential vulnerabilities and impact of foreign manufacturing.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Times
AUGUST 7, 2020
Scientists from the University of Oxford say the drug is being ‘discarded prematurely’
pharmaphorum
AUGUST 5, 2020
The UK government has asked pharma companies to build a six-week stockpile of drugs and find alternative shipping routes to the congested Dover-Calais crossing as the country heads for Brexit at the end of the year. In a letter , Steve Oldfield, chief commercial officer at the Department of Health and Social Care, said the government is focused on preventing potential disruption to any categories of medical supplies.
Outsourcing Pharma
AUGUST 3, 2020
Neurasic Therapeutics is borne from a collaborative effort intended to advance development of opioid-alternative pain relief.
Med Ed 101
AUGUST 5, 2020
While not incredibly common, medications can cause dysregulation of our body’s thermoregulation process and cause a rise in core temperature in the presence of normal core body temperature which leads to hyperthermia. Before we get to the drugs that cause hyperthermia, let’s review thermoregulation. Our body is able to regulate our core temperature to keep […].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
AUGUST 4, 2020
New deal with Wockhardt boosts capacity at the crucial 'fill and finish' stage
pharmaphorum
AUGUST 4, 2020
Sanofi has been placed under formal investigation in France for possible charges including manslaughter relating to the epilepsy drug Depakine, following the deaths of four babies whose mothers took the drug. Depakine was found to carry a high risk of birth defects if taken by pregnant women. Sanofi , which denies wrongdoing and says it warned of the risks long ago, is already being prosecuted in France following allegations it provided misleading information about the drug.
Outsourcing Pharma
AUGUST 6, 2020
A leader from the scientific software provider discusses the most challenging obstacles in the pharma supply chain, and solutions that can conquer them.
Med Ed 101
AUGUST 2, 2020
As of August 1st, 2020, pharmacogenomics has been added to the BCMTMS exam content outline. We’ve updated our material to include a review of pharmacogenomic principles and common medications that may be affected by genetic variations. In addition, we’ve added pharmacogenomics quiz questions to our quiz bank. I wanted to share a sample of our […].
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
AUGUST 3, 2020
Collaboration will explore experimental treatment IMM-101 in combination with other therapies in advanced cancers
pharmaphorum
AUGUST 7, 2020
Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. Find out more in our roundup of the biggest R&D, market access and digital stories from the past week. The perception of pharma and medical companies has surged upward since the start of the COVID-19 pandemic, but they still lie mostly outside the top-rated firms in the FutureBrand Index.
Outsourcing Pharma
AUGUST 6, 2020
The agency continues to provide resources for the life-sciences industry, approve tests, and take action against companies offering false treatments.
Pharma Tutor
AUGUST 5, 2020
Pharma Times
AUGUST 5, 2020
AZ will pay $17m in early milestone payments for the UK biotech’s fibrotic asset
pharmaphorum
AUGUST 5, 2020
The UK digital mental health support platform Kooth has joined with five of the UK’s well known Instagram influencers to launch a campaign to help students deal with the pressures of exam results season. The campaign encourages the hundreds of thousands of students waiting to receive their exam results, to stay mentally strong and know they have access to support, if needed.
Outsourcing Pharma
AUGUST 6, 2020
A leader from IBM Watson Health talks about how its advanced EDC solution is geared toward helping studies save precious time and conserve costs.
pharmaphorum
AUGUST 7, 2020
Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion. Denali has been working on small-molecule compounds capable of crossing the blood-brain barrier and Biogen has bought a licence to co-develop and co-market compounds known as LRRK2 inhibitors in Parkinson’s disease.
pharmaphorum
AUGUST 7, 2020
Health technology firms Cerner and LRVHealth have invested $6 million in Xealth to scale up its business offering digital health tools to patients and clinicians. The companies said the new relationship aims to give patients control over their own digital data so they can be more engaged in their treatment plans. Cerner and LRVHealth join Xealth’s other investors Atrium Health, Cleveland Clinic, Froedtert and the Medical College of Wisconsin, MemorialCare Innovation Fund, Providence Ventures and
pharmaphorum
AUGUST 5, 2020
The perception of pharma and medical product companies has surged forward since the start of the COVID-19 pandemic, but they still lie mostly outside the top-rated firms in the FutureBrand Index. Roche, AstraZeneca, Novo Nordisk, and Sanofi all shot up the rankings in the first edition of the report since the start of the coronavirus crisis, but the big loser was Gilead Sciences, falling 71 places to 74 in the list since the last edition in 2018.
pharmaphorum
AUGUST 5, 2020
The current level of test and trace in the UK is inadequate to prevent a sharp increase in coronavirus infections when schools reopen in September and there is further relaxation of social distancing rules, according to scientists. A second wave of COVID-19 could be avoided if enough people are tested and traced, according to the team from University College London and the London School of Hygiene & Tropical Medicine.
pharmaphorum
AUGUST 7, 2020
Roche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been dashed by a late-stage trial failure looking at the drug in combination with chemotherapy. Adding Tecentriq to treatment with paclitaxel as a first-line treatment for TNBC patients whose tumours expressed the biomarker PD-L1 did not lengthen the time it took for the cancer to progress, when compared to paclitaxel plus placebo.
pharmaphorum
AUGUST 6, 2020
Lundbeck has axed a phase 2 trial of a schizophrenia drug, saying that the study was unlikely to meet its efficacy target. The company said it made the decision after a futility analysis indicated that the trial was not likely to succeed, when measured against a standard scale. When Lundbeck began the trial at the beginning of last year, it said the drug could be a new approach to treating schizophrenia.
pharmaphorum
AUGUST 6, 2020
Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial. The CROWN trial pitted Lorbrena (lorlatinib) against Xalkori (crizotinib) in patients with previously-untreated ALK-positive non-small cell lung cancer (NSCLC), and showed that Lorbrena was better at staving off progression of the disease.
pharmaphorum
AUGUST 6, 2020
When aiming to reach the people who will benefit most from a given medication or therapy, patients who play an active role in treatment decisions are often at the forefront of the conversation. But what does playing an active role in treatment really mean? While there is no concrete definition, a meta-analysis of Health Union’s 2019 large scale, condition-specific In America surveys uncovers certain attitudes and behaviors associated with this mindset.
pharmaphorum
AUGUST 6, 2020
Denmark’s Novo Nordisk has beaten profit forecasts in the second quarter after overcoming tough conditions in the diabetes market by improving its productivity. Novo said that COVID-19 has begun to affect sales, with fewer new starts as a result of social distancing measures. The company’s diabetes care products saw an increase in sales during the second quarter, although this was offset by lower sales of insulin.
pharmaphorum
AUGUST 5, 2020
SMi reports: Brian Levy, CEO, Ocunexus Therapeutics will lead the post conference workshop on Wednesday 25 th November 2020. SMi presents the 4 th Annual Ophthalmic Drugs Conference taking place on the 23 rd -24 th November 2020, in London. SMi are also pleased to announce that they will be hosting a half-day post-conference workshop, Wednesday 25 th November 2020 at 13.30 – 17.30.
pharmaphorum
AUGUST 5, 2020
SMi Reports: Due to the ongoing challenges surrounding COVID-19 and large public gatherings, September’s Pre-filled Syringes San Francisco conference will now run as a virtual event. With the continued uncertainty surrounding large gatherings in the UK, SMi Group have made the decision to turn the pre-filled Syringes Conference on the 14h – 15th September 2020 into a fully interactive virtual meeting.
pharmaphorum
AUGUST 5, 2020
Merck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson & Johnson, into a therapy for the fatty liver disease known as NASH. Non-alcoholic steatohepatitis, as the disease is also known, has been a target for pharma for years but is proving a tough nut to crack as there are no drugs yet approved to treat it.
pharmaphorum
AUGUST 5, 2020
DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. The France-headquartered biotech confirmed the complete response letter (CRL) from the US regulator today, adding another delay to a programme that is already falling well behind a rival therapy developed by Aimmune – Palforzia – which was approved in February.
Expert insights. Personalized for you.
118 
Let's personalize your content